Actuate Therapeutics, Inc. (ACTU) stock
ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.02 (-6.12%)
Close on Nov 17, 2026Market cap $6.04MP/E –Yield –
Actuate Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Actuate Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$16.11M. For fiscal 2025 it was -$19.21M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.21M | – |
| FY2024 | Dec 31, 2024 | -$21.84M | – |
| FY2023 | Dec 31, 2023 | -$21.63M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.95M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.67M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.64M | – |
See a number that looks wrong?